Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Short Interest Update

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totaling 3,567,900 shares, a growth of 172.3% from the June 15th total of 1,310,364 shares. Based on an average trading volume of 1,355,663 shares, the days-to-cover ratio is presently 2.6 days. Approximately 5.8% of the shares of the stock are short sold.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Ikarian Capital LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $6,574,000. Boothbay Fund Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $2,204,000. Jain Global LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at $2,774,000. Remedium Capital Partners LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at $2,772,000. Finally, Geode Capital Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at about $266,000. Institutional investors and hedge funds own 14.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Wedbush restated an “outperform” rating and issued a $35.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, June 12th. Evercore started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, March 25th. They set an “outperform” rating and a $46.00 target price for the company. HC Wainwright assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 11th. They set a “buy” rating and a $45.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 18th. Finally, TD Cowen initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, June 8th. They set a “buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.43.

Damora Therapeutics, Inc. Common Stock Trading Up 0.7%

Shares of Damora Therapeutics, Inc. Common Stock stock traded up $0.21 during trading on Wednesday, reaching $31.20. The company’s stock had a trading volume of 416,425 shares, compared to its average volume of 382,580. The stock has a 50-day moving average price of $24.50 and a two-hundred day moving average price of $25.50. The stock has a market capitalization of $1.92 billion, a P/E ratio of -5.59 and a beta of 1.46. Damora Therapeutics, Inc. Common Stock has a one year low of $2.45 and a one year high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). As a group, sell-side analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current fiscal year.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.